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In the last three to four decades, the increasing caesarean delivery 
rate has contributed to several fold increment in the incidence of 
placenta accreta spectrum disorders globally. Placenta accreta 
spectrum with its subtypes (accreta, increta and percreta) is one of 
the devastating obstetric complications. As a result, it is the 
commonest indication for peripartum hysterectomy and common 
cause of severe maternal morbidity. However, in recent years, there 
is a growing interest in and practice of expectant management 
either to minimize emergency hysterectomy related maternal 
complications or to preserve the fertility potential of a woman with 
an intact uterus. A large body of observational research findings 
has demonstrated the success rate of expectant management in 
many of well selected cases. Similarly, the experience on delayed 
hysterectomy was encouraging in order to have less hemorrhage. 
For the best success of placenta accreta spectrum management, 
multidisciplinary team approach, antenatal diagnosis and 
managing such cases in a hospital with center of excellence has 
been strongly recommended. This literature review provides a 
robust synthesis of up-to-date knowledge and practice on the 
challenges and successes of placenta accreta spectrum disorders 
management. The currently practiced management options in the 
high and middle income countries are also summarized under 
seven categories. Therefore, the purpose of this review was to shed 
light on the applicability of the PAS disorder management 




Placenta accreta spectrum (PAS), first described in 1937 (1), refers to 
the pathologic invasion of the placental trophoblasts to the 
myometrium and beyond, which was formerly known as morbidly 
adherent placenta with subtypes described as accreta (adheres to the 
myometrium), increta (invades deep to the myometrium) and 
percreta (the invasion reaches to the uterine serosa and beyond) (2).  
Why the placenta gets infiltrated deep to the myometrium is not 
exactly known. Taking the strong association of PAS with uterine 
scar, defective decidualization at the endometrium–myometrium 
interface is usually attributed to its occurrence (3), but that does not
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exclusively explain the whole picture. Infrequently, 
PAS occurs in the first pregnancy. The rare variety 
of PAS which one of the authors experienced is the 
growth of the significant part of the placenta in the 
utero-vesical pouch passing through the uterine 
window of caesarean section (CS) scar while the 
fetus and part of the placenta was on the inside wall 
of the placenta. Placenta percreta extending beyond 
the uterine surface is not uncommon.    
The global incidence of PAS is not known 
because of the paucity of data from developing 
countries. In the United States of America (US), for 
instance, the incidence of PAS rose from 1 in 2510 
to 1 in 4017 between 1970s and 1980s (4) to 1 in 
272 in 2016 (5), which is about 10-15-fold 
increment in the last three to four decades. Its 
incidence was much higher in women with 
placenta previa and/or scarred uterus (6,7). The 
finding of anterior low lying or major placenta 
previa with a previous CS scar was highly 
indicative of the possibility of PAS, which is still a 
reminder that such cases require thorough 
ultrasound screening by an expert in the field 
starting from 18 weeks’ gestation (5,6).  
In general, the increasing number of CS 
delivery across the world is highly incriminated for 
the progressively increasing incidence of placental 
adherence (8). A meta-analysis of 11 case–control 
and 5 cohort studies showed about 2-fold increased 
risk of the PAS disorder after CS (9). Women with 
three or more uterine CS scar were more than 10 
times at higher risk of PAS than women with single 
uterine scar, which indicates the increased risk of 
PAS as the number of CS scar increases.  
In agreement with this finding, a systematic 
review reported the incidence of PAS as 3.3%-4% 
in women with placenta previa with no CS scar and 
50–67% in women with three or more CS scars 
(10). About a decade back, another study reported 
that women presenting with placenta previa and 
prior CS, the incidence of PAS was 3%, 11%, 40%, 
61% and 67% for one, two, three, four, and five or 
more CS deliveries, respectively (11).  Other risk 
factors attributed to PAS are also related to surgical 
and infectious injuries, which potentially can cause 
scar to the uterine wall (previous history of PAS, 
current placenta previa, previous myomectomy, 
metroplasty, endometrial ablation, Asherman’s 
syndrome, excised uterine polyp, repaired uterine 
perforation or rupture, endometrial curettage and 
previous endomtritis) (5,8).  
The immediate common complication of PAS 
is postpartum hemorrhage (PPH). Some call PAS 
the ‘nightmare’ of obstetricians (because of the 
massive hemorrhage encountered during an attempt 
of manual removal or during surgical excision of 
PAS involving extrauterine organs, and during 
caesarean hysterectomy) (12). The very severe 
complications (moribund hemorrhagic shock 
during delivery and uterine rupture before the onset 
of labor and usually early in pregnancy) are 
commonly encountered in women with placenta 
percreta (13-15). As a result, PAS is known to 
increase the relative risk of maternal death (16), but 
varies with the time of detection and subsequent 
interventions. PAS is also a common indication for 
peripartum hysterectomy. For instance, in the US 
and Australia, peripartum hysterectomy was the 
indication for 38% and 70% of peripartum 
hysterectomies, respectively (17).    
The progressively increasing incidence and the 
challenge in its management of the day-to-day 
practice is the main reason that urges the authors to 
go for in-depth review of literature and discuss the 
management challenges and the possibility of 
expectant management in our setup when 
conditions are against with hysterectomy or a 
woman badly need preserving her uterus. Of note, 
planned or emergency caesarean hysterectomy has 
been the standard practice globally, and in our 
practice too, for all types of PAS with irremovable 
placenta or intractable PPH.  
However, there is a growing interest in and 
practice of expectant management of PAS 
primarily to minimize fatal and highly morbid 
complication associated with immediate 
hysterectomy, and secondly to preserve the uterus 
when there is indication and preconditions fulfilled. 
Among others, the nearly a quarter success rate of 
pregnancies (18) after expectant management has 
motivated many obstetricians to consider the 
expectant management as one of the treatment 
modalities. Therefore, the purpose of this review is 
to provide an up-to-date evidence on the place of 
expectant management and let our obstetrician-
gynecologists make an evidence based decision in 
the management of the growing and challenging 
PAS disorders. 
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ANTENATAL DIAGNOSIS OF PAS 
The diagnosis of PAS is suspected antenatally via 
imaging, and confirmed clinically usually during 
CS, and occasionally with histopathologic 
examination of the hysterectomy or partially 
resected myometrial tissue. The antenatal diagnosis 
of PAS using imaging techniques is currently the 
gold standard and highly desirable to make a 
decision on the management plan and minimize the 
complications. From experience, it is known that 
the diagnosis of PAS is usually made intrapartum 
when exploration is done to spontaneously or with 
a simple cord traction undelivered placenta. Even 
in the developed world, three large case series 
studies have shown that 70% (19), 47% (20) and 
50% (21) of PAS cases were diagnosed during 
delivery.  
Antenatal diagnosis of PAS with one of the 
imaging technique (transvaginal ultrasound, color 
Doppler or MRI) is possible, preferably in the 
second and third trimester (5), but the detection 
capacity depends on the skill and experience of the 
examiner and the index of suspicion clinicians put 
forth. Therefore, the absence of suggestive imaging 
findings does not necessarily preclude the high 
index of suspicion, particularly in women with 
known risk factors.  
The ultrasonography finding in normal 
placental attachment is hypoechoic space between 
the placental body and the myometrium. In the 
morbidly adherent placenta, among several 
ultrasound signs, it is common to find a loss of the 
normal hypoechoic zone between the myometrium 
and the placenta. Instead, multiple placental 
lakes/lacunae (some call it ‘Swiss cheese’ or 
‘moth-eaten’ appearance within the placenta) and 
thinning of the utero-vesical wall in the anteriorly 
implanted placenta are usually seen (22). The same 
studies have reported that color flow Doppler 
imaging commonly shows the turbulent lacunar 
blood flow, an increase in sub-placental vascularity 
or vessels bridging the placenta to the uterine 
margin. Detail description of the diagnostic 
techniques and findings of PAS during imaging is 
beyond the scope of this article.  
The sensitivity of ultrasound in the 
diagnosis of placental adherence is reported to be 
good, but less sensitive and specific to measure the 
depth of invasion and lateral extension. A 
systematic review and meta-analysis done in 2017 
using the standardized ultrasound signs (using 2D 
gray-scale, 2D color Doppler or 3D color Doppler) 
have shown that the sensitivity and specificity of 
each was 97% (23).  
Another tool to diagnose placental 
adherence is MRI, with the additional advantage of 
assessing the depth of invasion and lateral 
extension (6). Although some authors reported that 
MRI is less preferred and is often misleading when 
used as an adjunct to ultrasound (24), a meta-
analysis has demonstrated that the overall detection 
of PAS with ultrasound and MRI is almost similar 
and its importance in diagnosing posterior PAS, 
degree of invasion and myometrial lateral 
extension is superior to ultrasound (25). Assessing 
the depth and lateral extension has management 
significance (3); as discussed below, the different 
options take into account the extent of placental 
infiltration and adjacent organs involvement to 
consider either expectant or radical management.  
It is noted that the sensitivity of MRI is 
better than Doppler ultrasound in detecting 
posteriorly implanted placenta, but the specificity 
of Doppler is much higher than the MRI in 
anteriorly and laterally implanted placenta with 
myometrial invasion. Since the majority of uterine 
scars are anterior, thereby the likelihood of PAS is 
more in anteriorly implanted placenta, and taking 
the cost and expertise, the importance of MRI is 
limited to only cases of diagnostic challenge. There 
are also some biomarkers of PAS disorders (alpha-
fetoprotein, beta-human chorionic gonadotropin 
and pregnancy-associated plasma protein A) whose 
benefit in the clinical setting is not yet well 
substantiated.  
Prognostic wise, a large body of 
observational studies has shown the reduced risk of 
maternal morbidity and mortality in antenatally 
diagnosed PAS disorders; it gives an opportunity 
for essential preparations and precautions, 
including multidisciplinary team management, 
making a decision to the time of delivery and 
providing prophylactic medical and surgical 
interventions (21,26-28). Management of 
accidently found PAS during delivery were 
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reported as commonly increasing the risk of life-
threatening complications. Among others, massive 
hemorrhage and blood transfusion requirement 
were very common in women who were diagnosed 
to have PAS in the third stage of labor as compared 
to antenatally diagnosed PAS cases (21,26,28-30).  
A report from Finland has shown that the 
range of blood loss among women who were 
diagnosed to have PAS antenatally and during 
delivery was 100-15,000 ml and 2500-17,000 ml, 
which required as high as 27 and 31 units of blood 
transfusion, respectively (28). Similarly, blood 
transfusion requirement in antenatally and 
intrapartum diagnosed PAS cases (increta and 
percreta) were 59% and 94%, respectively; the 
range of blood loss in the two groups was also 
statistically significant (250–10,514 ml in 
antenatally diagnosed versus 1500–24,000 ml in 
unsuspected cases) (21).   
In general, the antenatal diagnosis of PAS 
gives an opportunity not to go for forcible attempt 
of removal of the placenta, and get prepared for 
multidisciplinary team management thereby help 
reduce the blood loss and other complications. The 
multidisciplinary management has been shown to 
reduce the blood loss and improving the maternal 
and perinatal outcomes (6,27). Equally important, 
planned CS can be performed before the onset of 
labor.  
The antenatal diagnosis of PAS is also an 
advantage to administer corticosteroid, cross-match 
blood and counsel the woman still on the 
possibility of hysterectomy in a condition expectant 
management is favored. It is an opportunity to 
provide the basic information to women who 
preferred preserving her uterus to be aware of the 
increased risk of immediate complications (early 
and late PPH, infection, uterine necrosis, delayed 
hysterectomy, acute renal failure, coagulopathy, 
pulmonary embolism, sepsis) and long term 
complications of preserving it (recurrence of PAS, 
fistula, uterine window, pelvic adhesion and many 
more). Furthermore, it is an important evidence to 
refer the woman to a center where there are experts 
in both surgical and expectant management of PAS 
(27,30).  
The bottom line is that every pregnant 
woman with a previous uterine scar and/or 
diagnosed to have placenta previa need to be 
offered in-depth imaging evaluation for PAS, 
preferably by a radiologist.  
 
MAKING DECISION ON EXPECTANT 
MANAGEMENT OF PAS 
Although expectant management has been 
practiced since 1986 (31), it is still limited to 
certain areas and done for certain indications. In 
literature, expectant and conservative management 
is interchangeably used when the uterus is 
preserved after a morbidly adherent placenta is 
conservatively managed, usually with the intention 
of preserving the fertility. Conservative, literally, is 
to mean that the surgical interventions will not end 
up with removal of the uterus. Therefore, in the 
article, expectant management is consistently used. 
The most common indications for expectant 
management of PAS are preserving the natural 
fertility, delaying hysterectomy procedure or when 
the risk of bleeding due to radical surgery is 
assumed to outweigh the expectant management, 
particularly in case of triple or quadruple 
combination of complications (PAS, previa, 
adhesion and hemorrhagic shock), which all are not 
uncommon in pregnancy after previous CS (6). 
Therefore, expectant management is not only to 
preserve the uterus but also to prevent life-
threatening complications associated with manual 
placenta removal attempts or emergency caesarean 
hysterectomy (2).  
Placenta percreta-related infiltration to the 
adjacent structures (usually bladder, rarely other 
visceral organs) is another major reason not to 
attempt removal of the placenta and make a 
decision on expectant management. In such 
condition, going for primary hysterectomy or 
excision of the placenta from its extrauterine dense 
attachment is likely to result in torrential bleeding 
that may endanger the life of the woman (18).    
Specifically, when the urinary bladder 
invasion by the placenta is detected on ultrasound 
examination, preoperative cystoscopy and 
placement of prophylactic ureteral stents have been 
recommended (32). Similarly, for all major 
extrauterine invasions of the placenta, a 
multidisciplinary team approach (at least involving 
experienced obstetrician, urologist, anesthesiologist 
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and neonatologist) can minimize the anticipated 
massive hemorrhage and further complications.  
In antenatally diagnosed PAS, the surgical 
management options with different scenarios have 
to be exhaustively discussed among the managing 
team for the benefit of the doubt and making 
everybody on board during the procedure and the 
postpartum follow-up period. Involving the woman 
in the decision making is always a wise practice as 
there are conditions that make the caesarean 
hysterectomy a must while the plan is to go for 
expectant management.  
Secondly, the caesarean hysterectomy for PAS 
may complicate with massive hemorrhage 
requiring blood transfusion, injury to the bladder, 
ureter and bowel, and postpartum infection (33,34). 
As noted earlier, the requirement of many units of 
blood, the conservative and radical surgical 
techniques, the increased likelihood of having as 
well placenta previa and premature delivery, and 
increased chance of admission to the intensive care 
units (ICU) warrant the management of PAS in a 
hospital which has developed the excellence in 
handling similar cases (5). Specifically, if placenta 
percreta is diagnosed antenatally, all efforts should 
be made to transfer the woman to a higher center, 
as it is likely to seriously complicated with (19).  
Although antenatal diagnosis of PAS has 
multiple advantages, there is no accessible 
randomized clinical trial that assessed the timing of 
delivery. One guideline recommends a similar 
approach to placenta previa (planned CS if late at 
37 weeks’ gestation) (6). However, the strong 
association of PAS with placenta previa may let 
dictate earlier termination of pregnancy if there is 
active bleeding due to the latter problem. 
Otherwise, at present, there is no good evidence 
that supports termination of pregnancy in the 
second trimester for the suspected PAS of any 
degree (5).  In general, an expectant management 
decision is made when the fertility need is high or 
hysterectomy carries an unacceptably high risk to 




MANAGEMENT OPTIONS FOR WOMEN 
WITH PAS 
 
Our literature review has identified several options 
of management in women with PAS. Each option 
has its own risks and benefits. The choice of the 
PAS management options depends on the skill of 
the surgeon to perform hysterectomy in a bloody 
condition, the hemodynamic status of the patient to 
tolerate anesthesia and further blood loss, the need 
of preserving the uterus, the ability to secure 
hemostasis while the placenta is in situ, the 
warranty of anticipated adherence to follow-up and 
the health facility setup for serial measurement of 
placental regression (35).  
The summary of the different management 
options of PAS (as compiled from different 
literature to fit for the purpose) is presented below.  
All management options take third trimester 
pregnancy into consideration.  
Option I (direct hysterectomy): Elective or 
emergency caesarean hysterectomy, without 
attempting removal of the placenta, is the usual 
practice in morbidly adherent placenta (36). In this 
scenario, the diagnosis of PAS can be made 
antenatal or intrapartum after vaginal or abdominal 
delivery. The decision is made straight to go for 
immediate hysterectomy.  
To the authors’ knowledge, in this country, 
for all manually irremovable PAS cases usually 
diagnosed in the third stage of labor, emergency 
hysterectomy is performed. Direct hysterectomy is 
also a preferred option elsewhere in women who 
completed their fertility, hemodynamically stable 
and when the setup enables performing emergency 
or elective hysterectomy.  
A very recent single-center experience report 
from Canada has also shown that all women with 
PAS were provided caesarean hysterectomy. If 
hysterectomy is decided, both subtotal and total 
hysterectomy procedures are options (21,37,38); 
the decision is made based on the hemodynamic 
status of the patient, absence or presence of major 
degree placenta previa and the skill of the surgeon. 
However, FIGO stated that caesarean hysterectomy 
is associated with 40%–50% increased risk of 
severe maternal morbidity. In women with placenta 
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percreta, the mortality rates can be as high as 7%, 
mainly due to pelvic organs injury and massive 
hemorrhage (2). The risks of mortality and severe 
morbidity increases in cases of placenta percreta 
managed with emergency caesarean hysterectomy. 
Although compared to other types of PAS, it is still 
at higher risk of complications, placenta percreta 
left in situ for delayed hysterectomy or 
spontaneous resorption has a better prognosis (39).   
Option II (delayed hysterectomy): Delayed 
hysterectomy is preferred when 1) fertility and 
keeping the uterus is not a priority; 2) the case is 
not a good candidate for expectant management; 
and 3) the woman is not eligible or the setup is not 
conducive to perform an immediate hysterectomy. 
Specific to the latter, as noted earlier, it is common 
to diagnose placental adherence during CS with no 
preparation or capacity to go for a hysterectomy or 
to counsel the woman. In such circumstance, 
provided that there is no active bleeding or 
conservatively controlled, the abdomen can be 
closed, and the woman can be transferred to a 
center where multidisciplinary experts of a team 
are available.  
Women diagnosed to have placenta 
percreta, in particular, can benefit a lot from 
delayed hysterectomy and multidisciplinary team 
management (40). Technically, after delivery of the 
fetus, the placenta is left in situ without attempting 
removal, by ligating and cutting the umbilical cord 
near the placental insertion, closing the uterine 
incision, and performing elective secondary 
hysterectomy 6-10 weeks after the delivery of the 
baby (41) unless complications warrant earlier 
delayed hysterectomy. A delay up to the first 24 
hours (probably till the patient is in the hand of the 
right person) still belongs to option I management.  
This option is also applicable to vaginal 
delivery by ligating and cutting the umbilical cord 
too short to let it stay inside the uterus, after the 
PAS is highly suspected with one of the imaging 
modalities. The advantage of delayed over the 
immediate hysterectomy is reduced blood loss and 
inadvertent injury to adjacent structures. Delayed 
hysterectomy is less risky in hemodynamically 
stable women with no sign of placental separation 
and/or no bleeding. Bladder injury is very common 
in emergency caesarean hysterectomy and placenta 
percreta cases (40,42).  
This option is not at all recommended in 
women whereby active bleeding could not be 
controlled, coagulopathy or infection has already 
developed or the risk is high. In case, the bleeding 
persists or starts to be in an uncontrollable state, it 
is likely that the placenta is partly separated and 
partly adherent. All efforts should be devoted to 
stop the bleeding, by applying conservative or 
radical surgical interventions.    
As discussed below in other options, apart 
from administering Tranexamic acid, either 
conservative surgeries (like removal of the placenta 
in piecemeal with sponge forceps after vaginal 
delivery, with fingers after CS delivery, followed 
by the insertion of a uterine tamponade device or 
the application of uterine compression sutures 
and/or uterine vessels devascularization) or 
performing hysterectomy should not be delayed. 
This should be the management principle in 
options III-VI too.  
Option III (expectant management with no 
attempt to remove the placenta and with no 
uterine devascularization or compression): 
Expectant management without attempting removal 
of the placenta encompasses administering 
prophylactic Tranexamic acid after clamping and 
cutting the cord too short (6,43), closing the uterine 
incision in cases of CS, and observing for active 
vaginal bleeding. The intention is to preserve the 
uterus by expecting spontaneous placental 
resorption without uterine devascularization or 
compression intervention. Cases managed with this 
modality usually start to have vaginal bleeding 
after several days or weeks; when the placenta 
becomes necrotic, there is a chance of spontaneous 
separation and bleeding, which can be removed by 
ultrasound guided hysteroscopic resection. 
However, metallic curettage should not be 
attempted.  
Like in option I, this option best fits for 
cases of PAS with no placental separation in the 
third stage of labor or no inadvertent or intentional 
disruption of the placenta. However, it can also be 
applied after partial placental separation if the 
Tranexamic acid or uterotonics (other than 
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oxytocin) controls the active bleeding, and 
hemostasis is secured. A recent systematic review 
of placenta percreta cases has shown that the 
success of uterine preservation without any 
conservative surgical interventions was 39%, 
which is lower than other types of PAS disorders, 
and with high maternal morbidity during the period 
of conservative management (42).  
In one study, significant blood loss or 
uncontrolled bleeding was an indication for 
immediate hysterectomy after an expectant 
management decision was made with no attempt to 
remove the placenta in 31.4% (44). Particularly, in 
women with antenatal evidence of deep invasion, 
an attempt to remove the placenta was reported to 
be bloody, and it was a common indication for 
hysterectomy in 24 hours of delivery (18,25,44).  
In this kind of expectant management, what 
is most important is ascertaining the diagnosis of 
PAS (particularly, in cases of vaginal delivery) and 
close follow-up for active vaginal bleeding, 
infection and coagulopathy, and taking immediate 
action when complications encountered. In other 
words, this modality cannot be an option in women 
with active bleeding in either vaginal or CS 
delivery, in women with evidence of coagulopathy 
and uterine infection. In successful cases, the 
expectant management ends up with an empty 
uterus after spontaneous expulsion or assisted 
removal or complete resorption of the placenta.  
Option IV (expectant management with 
conservative intervention to prevent PPH): After 
delivery of the fetus and prophylactic Tranexamic 
acid is administered like in option III, one or two 
possible PPH prophylactic surgical or radiologic 
measures are performed. Depending on the setup 
and managing team preference, specific procedures 
selectively performed include uterine 
devascularization (major arteries ligation, arterial 
embolization, occlusion of the major arteries by 
placing intra-arterial balloon), applying uterine 
compression sutures, and inserting one of the 
intrauterine balloon tamponade devices (Bakri 
balloon, condom catheter, Foley catheter, 
Sengstaken–Blakemore oesophageal catheter, and 
the urological Rusch balloon) (45-47). 
Applying these techniques is easier when 
the surgery is performed on elective base. 
Compression sutures and devascularization can be 
performed with the whole placenta is in situ or 
partly removed in both non-bleeding and actively 
bleeding uterus. Balloon tamponades are usually 
applied to arrest active bleeding. Among the 
balloon tamponades, one small case series study 
reported that inserting Bakri balloon prevented 16 
out of 19 cases from hysterectomy by effectively 
controlling the bleeding from the placental bed 
because of the large volume it accommodates in 
(45). In our setting, the widely available condom 
catheter can be used.  
Cervix as natural tamponade (by inverting 
the anterior or posterior lip of the cervix and 
suturing with the placental bed in the anterior or 
posterior wall of the uterus) was also reported from 
Egypt as safe, simple, time-saving and effective 
method for controlling PPH caused by placenta 
previa or placenta previa accreta (48). The same 
authors reported cervical tamponade with bilateral 
uterine artery ligation and removal of the placenta 
after a month on elective base as a safe alternative 
method to hysterectomy in those women who wish 
to preserve their fertility (49).  In general, the 
devascularization procedures in option IV are not 
limited to the bilateral anterior division of internal 
iliac artery ligations like Shabana and colleagues 
‘stepwise approach’, it entertains multiple 
alternative modalities.   
Beyond the immediate actions, ultrasound 
guided hysteroscopic placental morcellation can be 
performed in between if there is transcervically 
accessible placental tissue which is amenable for 
resection. Hysteroscopic resection of retained 
placental tissue after some time was successful by 
avoiding hysterectomy in 11 out of 12 symptomatic 
women (50). It can be attempted under ultrasound 
guide in women with secondary bleeding due to 
significant placental tissue, which is accessible 
through the endometrial cavity. Such procedure is 
an advantage both to arrest the bleeding and 
shorten the placental resorption time.  
In our common clinical practice, the 
successful removal of adherent placenta (usually 
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accreta type) and controlling the bleeding with 
arteries ligation or compression methods or some 
other technique still belongs to this option.  
Option V (expectant management with Triple-P 
procedure: Triple-P procedure is a variety of 
option IV. It is applicable in antenatally diagnosed 
PAS cases. The procedure includes 1) preoperative 
localization of the superior edge of the placenta; 2) 
pelvic devascularization by placing intra-arterial 
balloon catheters (at anterior division of the 
internal iliac arteries) before the surgery; and 3) 
placental non-separation with myometrial excision 
(limited excision of the myometrium with part of 
the placenta and closure of the defect to reduce the 
blood loss) (51). The temporal internal iliac balloon 
occlusion, as part of the Triple-P procedure or 
alone, however, is still highly controversial because 
of the increased risk of complications, including 
vessels rupture, ischemic injury and thrombus 
formation (52-55). As a result, FIGO recommended 
further study before this technique can be offered 
in the management of PAS disorders (2). PAS 
cases with extensive lateral or cervical invasion are 
not suitable for local resection. Otherwise, a bit 
similar surgical procedure was practiced in 
Argentina more than a decade before the Triple-P 
procedure.  
Option VI (resection of all invaded myometrial 
tissue and expectant management): Resection of 
all placenta invaded myometrial tissue (some call it 
one-step conservative surgery) (55) is performed 
after delivery of the fetus and after the extent of 
placental invasion is grossly estimated. The 
procedure is completed by suturing the defect, 
securing hemostasis and administering Tranexamic 
acid, but without devascularization and other PPH 
surgical prophylactic measures.  
The advantage of this procedure is almost 
entirely to remove the placental mass from the 
uterine wall. However, as the uterus is highly 
vascular organ during pregnancy, there may be 
massive hemorrhage, particularly in laterally 
implanted placenta and placenta percreta cases 
(42). When the excision is wide enough, the 
approximation will not be easier and is liable to 
uterine window formation. Thirdly, the extensive 
damage to the myometrial wall may increase the 
risk of scar dehiscence in subsequent pregnancies.  
Option VII (manual removal of the placenta): In 
women with placenta accreta, actively bleeding, 
and cleavage plane appreciated, manual removal of 
placenta (if possible in totality, if not in piecemeal) 
accompanied by Tranexamic acid administration 
and intrauterine tamponade is lifesaving procedure. 
However, attempting manual removal of the 
placenta in cases of placenta increta and percreta is 
a very dangerous practice, which usually ends up 
with massive hemorrhage requiring emergency 
hysterectomy (46).  
Many other authors also described such 
vigor as having devastating consequences to the 
mother by resulting in massive hemorrhage, 
disseminated intravascular coagulation and 
postpartum infection (6,7,35,36). Therefore, if the 
diagnosis of PAS is made in the antenatal period 
and caesarean hysterectomy is decided, there is no 
need to attempt manual removal of the placenta 
(6,35,36). Similarly, for PAS cases detected during 
CS, one should not go for forcible removal of the 
placenta; rather, involving the most senior person 
on what to do next is a wise decision. If there is no 
active bleeding, there is no need to rush for any 
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Table 1: Review of case series studies (with > 30 cases included) on expectant management of placenta 
accreta spectrum disorders 
 
 








Conservative surgical and radiological 
interventions  
Sentilhes L et al, 1993-






Placenta was left in situ partially in 99 and 
entirely in 68; primary and secondary uterine 
devascularizations were done in 109 and 57, 
respectively; methotrexate was given in 21 
cases. 
Marcellin L et al, 2003-
2017, France (44) 
107 86(80.4%) Bilateral hypogastric artery ligation for 23 cases; 
pelvic arterial embolization for 26 cases; 
preoperative balloon catheter was placed for 7 
cases. 
El Gelany S et al, 2017-





Cervical tamponade with bilateral uterine artery 
ligation for 48 cases; Postoperative uterine artery 
embolization and removal of the placenta after a 
month for 10 cases.  
Timmerman S et al, 1985-
2006, multi-country (60) 
60 48(80%) Methotrexate was given in 22; selective arterial 
embolization for 12 and no intervention for 26 
cases.  
Zhang C et al, 1998-2010, 
China (61) 
54 50(92.5%) Methotrexate: IV injection for 21, success in 17 
(Group 1); multipoint placental injection for 33, 
success in all (Group II). 
Bailit JL et al, 2008-2011, 
US†† (20) 
158 48(30.4%) Balloon tamponade for 5, B-Lynch suture for 3, 
two or more uterotonics other than oxytocin for 
17 and artery ligation for 2 cases.  
Palacios-Jaraquemada JM 
et al,  1995-2003, 
Argentina (62) 
68 50(73.5%)†† Uterine devascularization by artery ligation for 
57 and B-Lynch suture for 5 and local square 
sutures for 15 cases.   
Mei J et al, 2010-2013‡ 
(63) 
177 159(90%) Arterial embolization for all cases.  
Mei J et al, 1980-2012‡ 
(63) 
76 48(63%) Uterus preserving surgery for all (hemostatic 
sutures and arterial ligation) 
Mei J et al, 2007-2012‡ 
(63) 
42 33 (79%) Artery occlusion balloon for all 
Matsuzaki S et al, 1990-
2016‡ (42) 
68  42(61.8%) Prophylactic, therapeutic uterine artery 
embolization and both for 33, 11 and 3 cases, 
respectively; methotrexate for 27 and etoposide 
for 3 cases.  
Clausen C et al, 2013‡ (40) 53 ʃ 32(60.4%) Arterial embolization for 23, embolization and 
balloon occlusion for 4 and balloon occlusion 
only for 16 cases.   
Pather S  
et al, 1995-2012‡ (64) 
60   36(60%) Pelvic embolization for 28, methotrexate for 20, 
both for 11 and other procedures for 13 cases.  
†From 25 university hospitals; 10 of 18 placenta percreta cases were successful. ††From 25 hospital. †24 became 
pregnant. ††10 became pregnant in 3 years. ‡ Review.  All were placenta percreta cases. ʃ Placenta left in situ (n=36) 
and local resection done (n=17) 
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Since all PAS management options are not yet well 
substantiated with well-designed randomized 
clinical trials data, option I (when conditions allow) 
and option II (buying some time for the patient to 
be hemodynamically stable, uterine and placental 
size shrunk) are plausible decisions that need to be 
made for a woman who completed her family or 
have another reason that precludes her from 
expectant management. Option III cannot be 
planned without adequate preparation for 
immediate surgical intervention and blood 
transfusion. In our setup, option III shall be 
considered watchfully in tertiary centers with 
adequate blood products, adult ICU as a backup 
and optimal laboratory setup for follow-up.    
Option IV may fit best for our tertiary 
setting when expectant management is antenatally 
decided; at least surgical devascularization or 
compression sutures can be applied. Option VI and 
VII are the riskiest in terms of experiencing 
massive hemorrhage, and are not a good choice for 
us as there is meagre access to blood products for 
transfusion in almost all health facilities. Option 
VII, in particular, usually ends up with salvage 
hysterectomy and life threatening condition in 
women with deep placental invasion.  
Selecting the appropriate candidate for 
expectant management, to the best with prenatal 
diagnosis and ahead planning the type of surgery, 
and involving the locally available experts in the 
field, is a pragmatic decision (26, 28). By any 
standard, preserving the uterus never ever be with 
the expense of significant blood loss that may 
endanger the life of the mother. ACOG also 
recommends expectant management only for 
carefully selected cases with adequate counseling 
on potential risks (5).    
In case expectant management (option III-
VI) is decided, prophylactic antibiotic (amoxicillin 
or clindamycin) (2) and Tranexamic acid 
administration should be routine. The 
recommendation on prophylactic Tranexamic acid 
is based on the observed significant reduction of 
hemorrhage during CS (56), and with the 
assumption that if placenta starts separating 
spontaneously, it can reduce the blood loss.  
The resorption of placenta left in situ is 
assessed by weekly measuring the placenta mass, 
determining the beta-human chorionic 
gonadotropin (beta-hCG) levels, and the 
uteroplacental arterial circulation using Doppler 
ultrasound. It should also be well noted that beta-
hCG may be undetectable while the placenta mass 
is still there (2). Therefore, the drop of beta-hCG 
level should be complemented by transvaginal 
unmeasurable placental mass. The follow-up 
should also give emphasis to an assessment of the 
hematologic profile for coagulopathy and infection.   
Spontaneous resolution of the placenta 
percreta and increta may take 1-12 months. Early 
and late PPH is the most common complication of 
expectant management (18). Other less common 
complications in the postpartum period include 
DIC, endomyometritis, and sepsis. In subsequent 
pregnancies, there is an increased risk of recurrent 
PAS, PPH, uterine rupture, and peripartum 
hysterectomy (57-59).  
In general, expectant management of PAS 
is not a decision to be made because the woman 
requests preserving her uterus. Risks have to be 
weighed from a different perspective. It is highly 
recommended that such decision be made and the 
whole course of treatment and follow-up is in a 
tertiary center (26). This is because CS may require 
hysterectomy; expectant management may require 
some advanced surgical techniques to minimize 
complications, interventional radiology, and 
methotrexate administration although its 
importance is still uncertain (5,42). Furthermore, to 
have a better prenatal diagnosis, to provide blood 
transfusion, and to have close biochemical and 
imaging follow-up for placental status and 
complications, referring such cases to a tertiary 
center is highly recommended.  
Large case series studies (which had 
included >30 cases of expectant management) are 
summarized in Table 1 (18,20,40,42,44,49,62,60, 
61,63,64) to show the outcomes of uterine 
preserving interventions. As there were plenty of 
success stories in non-percreta cases, in terms of 
avoiding hysterectomy, there were also failures, 
primarily due to serious complications requiring 
immediate and delayed hysterectomy. In all these 
case series studies, the most challenging 
complication was PPH, which was actually the 
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major indication for both primary and secondary 
hysterectomies after a decision was made on 
expectant management.  
In the largest case series study with the 
highest success rate of expectant management 
(78.4%), more than half (51.5%) developed PPH, 
and PPH was the indication for all primary and 
44.4% of secondary hysterectomies (18). The 
second reason for the high failure rate of the 
expectant management was the type of PAS being 
placenta percreta. In general, the success rate of 
expectant management in women with placenta 
percreta was not as high as accreta and increta 
(40,42,65); failures were reported even after 9 
months of expectant management (40).  
In the majority of the included studies, 
uterine devascularization was the common 
procedure, and the proportion of uterine 
preservation was encouraging to do more. 
However, when the intention of preserving the 
uterus is maintaining fertility, the success of the 
expectant management is best measured by the 
number of pregnancies reaching third trimester. A 
follow-up study by including 96 cases who were 
managed expectantly concluded that expectant 
treatment did not appear to compromise the 
subsequent fertility or obstetric outcome; 24 
women were able to achieve 34 pregnancies. Of 
these, 21 were live births (66). Another study, 
which followed 68 cases for 10 years after 
expectant management, reported 272 deliveries, but 
with more than 15-fold increased risk of PAS 
recurrence (65).  
With regard to the use of methotrexate in 
the PAS expectant management, as there is no 
clinical trial that verifies its importance, many 
authors are not recommending it, primarily by 
taking into consideration the biology of the 
placenta. In other words, although there is a long 
experience in its use for placental tissue left in situ 
and thought to induce placental necrosis and rapid 
involution, currently, it is not recommended 
(2,35,42). A recent systematic review has also 
shown no statistically significant difference 
between chemotherapy received and control groups 
(42). The argument is that since the fetal placental 
circulation is interrupted and the placentas are 
usually somehow aged, trophoblastic cells 
proliferation will no more be active at and near 
term for the methotrexate to act (2,5).  
However, there are some success stories 
(spontaneous placental expulsion and faster 
complete involution) reported from the case series 
studies with methotrexate administration (67-69). 
A recent published study from China (including 54 
cases for expectant management) has reported a 
success rate of 92.5% by administering 
methotrexate intravenously or local multi-point 
injection under ultrasound guidance, with 100% 
success in the latter group (61). 
Of note, the potential side effect of 
methotrexate (including its safety margin for 
lactating mother) in the immediate postpartum 
women is not well known although there are few 
clearly associated complications, including massive 
hemorrhage, endomyometritis, sepsis (68), and one 
maternal death (21). There is no as well consensus 
on the optimal dose and the route of administration 
(some used trans-umbilical, others intramuscular). 
In one review, the dose of methotrexate ranged 
from 50 mg to more than 300 mg with variable 
rates of success (42). In short, till a good scientific 
evidence comes with randomized clinical trial, 
whether to include it in the expectant management 
package of PAS or totally exclude it, the decision is 
left to the managing team.  
The place of uterotonics in the management 
of PAS is also controversial. Some authors and 
guidelines recommended (61), but others are 
against, fearing the possible risk of partial placental 
separation and massive hemorrhage (70). In the 
largest case series study (18), all women were 
given uterotonics. In another study, one or more 
uterotonics (other than oxytocin) were also given in 
33 cases (20).    
In conclusion, the success rate of expectant 
management was better with one of the adjuvant 
interventions like arterial ligation, compression 
sutures and partial resection of the placenta, which 
can be practiced in our tertiary centers. The 
recently (2019) reported a high success rate of 
expectant management from Egypt with triple 
intervention (cervical tamponade, uterine 
devascularization and removal of the placenta 
within 32–72 days after delivery) (49) is a new 
experience, which may be considered in selected 
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cases. Expectant management should be considered 
when a woman is ineligible for primary 
hysterectomy and will not be harmed much by the 




• Since PAS shows an increasing trend with 
increasing CS rate globally, a high index of 
suspicion during the antenatal period makes the 
managing team better prepared for its early 
diagnosis and elective intervention.  
• Whenever a woman is antenatally diagnosed to 
have placenta previa in scarred uterus, she 
should be referred to an experienced 
radiologist with high index of suspicion to 
PAS.  
• For antenattally diagnosed PAS cases, elective 
caesarean hysterectomy is still the safest option 
for the majority of PAS cases not later than 37 
weeks of gestation.  
• There is a place of expectant management in 
Ethiopian setup at tertiary level for 
appropriately selected cases after developing a 
management protocol and making a 
multidisciplinary team management 
preparation. 
• Applying one or two of the four conservative 
surgical procedures (uterine devascularisation, 
compression sutures, uterine balloon 
tamponade, partial myometrial resection) or 
arterial embolization, and administering 
Tranexamic acid to all can increase the chance 
of uterine preservation.   
• All intrauterine pregnancies after expectant 
management of PAS should be considered as 
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